Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Jazz Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 9.0%. For fiscal 2025 it was -10.1%, against 17.6% the year before. The highest annual figure on record is 46.9% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -10.1% | −27.7 |
| FY2024 | Dec 31, 2024 | 17.6% | +2.5 |
| FY2023 | Dec 31, 2023 | 15.1% | +16.9 |
| FY2022 | Dec 31, 2022 | -1.8% | −7.3 |
| FY2021 | Dec 31, 2021 | 5.5% | −10.5 |
| FY2020 | Dec 31, 2020 | 16.0% | −8.6 |
| FY2019 | Dec 31, 2019 | 24.6% | −7.9 |
| FY2018 | Dec 31, 2018 | 32.5% | −0.2 |
| FY2017 | Dec 31, 2017 | 32.7% | −7.1 |
| FY2016 | Dec 31, 2016 | 39.8% | +1.4 |
| FY2015 | Dec 31, 2015 | 38.4% | +21.7 |
| FY2014 | Dec 31, 2014 | 16.7% | −22.3 |
| FY2013 | Dec 31, 2013 | 39.0% | +5.2 |
| FY2012 | Dec 31, 2012 | 33.8% | −13.2 |
| FY2011 | Dec 31, 2011 | 46.9% | +13.7 |
| FY2010 | Dec 31, 2010 | 33.3% | +20.9 |
| FY2009 | Dec 31, 2009 | 12.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -33.3% | −38.4 |
| Q2 FY2026 | Jun 30, 2026 | 20.5% | +86.2 |
| Q1 FY2026 | Mar 31, 2026 | 31.5% | +37.7 |
| Q4 FY2025 | Dec 31, 2025 | 21.2% | +3.7 |
| Q3 FY2025 | Sep 30, 2025 | 5.1% | −19.6 |
| Q2 FY2025 | Jun 30, 2025 | -65.6% | −85.1 |
| Q1 FY2025 | Mar 31, 2025 | -6.2% | −13.6 |
| Q4 FY2024 | Dec 31, 2024 | 17.5% | +5.4 |
| Q3 FY2024 | Sep 30, 2024 | 24.7% | +6.9 |
| Q2 FY2024 | Jun 30, 2024 | 19.5% | +3.0 |
| Q1 FY2024 | Mar 31, 2024 | 7.3% | −6.8 |
| Q4 FY2023 | Dec 31, 2023 | 12.1% | +39.2 |
| Q3 FY2023 | Sep 30, 2023 | 17.7% | +15.1 |
| Q2 FY2023 | Jun 30, 2023 | 16.5% | +7.3 |
| Q1 FY2023 | Mar 31, 2023 | 14.1% | +3.4 |
| Q4 FY2022 | Dec 31, 2022 | -27.1% | −32.6 |
| Q3 FY2022 | Sep 30, 2022 | 2.6% | −0.8 |
| Q2 FY2022 | Jun 30, 2022 | 9.2% | +18.4 |
| Q1 FY2022 | Mar 31, 2022 | 10.8% | −15.9 |
| Q4 FY2021 | Dec 31, 2021 | 5.5% | −20.6 |
| Q3 FY2021 | Sep 30, 2021 | 3.4% | −29.3 |
| Q2 FY2021 | Jun 30, 2021 | -9.3% | −44.5 |
| Q1 FY2021 | Mar 31, 2021 | 26.7% | +62.2 |
| Q4 FY2020 | Dec 31, 2020 | 26.1% | +15.5 |
| Q3 FY2020 | Sep 30, 2020 | 32.7% | +7.9 |
| Q2 FY2020 | Jun 30, 2020 | 35.2% | −3.0 |
| Q1 FY2020 | Mar 31, 2020 | -35.5% | −61.8 |
| Q4 FY2019 | Dec 31, 2019 | 10.5% | −28.3 |
| Q3 FY2019 | Sep 30, 2019 | 24.8% | −15.5 |
| Q2 FY2019 | Jun 30, 2019 | 38.2% | +7.6 |
| Q1 FY2019 | Mar 31, 2019 | 26.3% | +6.6 |
| Q4 FY2018 | Dec 31, 2018 | 38.8% | +6.5 |
| Q3 FY2018 | Sep 30, 2018 | 40.2% | +19.2 |
| Q2 FY2018 | Jun 30, 2018 | 30.6% | −11.2 |
| Q1 FY2018 | Mar 31, 2018 | 19.7% | −16.5 |
| Q4 FY2017 | Dec 31, 2017 | 32.4% | −9.4 |
| Q3 FY2017 | Sep 30, 2017 | 21.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 41.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 36.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 41.7% | – |
See a number that looks wrong?